Insider Selling: SiBone (NASDAQ:SIBN) Insider Sells $59,871.46 in Stock

SiBone (NASDAQ:SIBN) insider Anthony Recupero sold 3,833 shares of SiBone stock in a transaction on Monday, August 18th. The shares were sold at an average price of $15.62, for a total value of $59,871.46. Following the transaction, the insider owned 275,288 shares in the company, valued at $4,299,998.56. This trade represents a 1.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

SiBone Price Performance

NASDAQ SIBN opened at $16.39 on Friday. The company has a market capitalization of $707.06 million, a PE ratio of -29.27 and a beta of 0.91. The company has a debt-to-equity ratio of 0.21, a quick ratio of 7.00 and a current ratio of 8.38. The business’s fifty day moving average is $17.06 and its 200 day moving average is $16.54. SiBone has a fifty-two week low of $11.70 and a fifty-two week high of $20.05.

SiBone (NASDAQ:SIBN) last released its earnings results on Monday, August 4th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.05. SiBone had a negative return on equity of 14.20% and a negative net margin of 12.83%.The company had revenue of $48.63 million for the quarter, compared to the consensus estimate of $48.12 million. SiBone has set its FY 2025 guidance at EPS. Sell-side analysts predict that SiBone will post -0.78 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Truist Financial boosted their price objective on SiBone from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Tuesday, May 6th. Wall Street Zen downgraded SiBone from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Cantor Fitzgerald set a $25.00 price objective on SiBone and gave the company an “overweight” rating in a research report on Monday, August 11th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $24.00 target price on shares of SiBone in a report on Tuesday, May 6th. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $23.67.

Institutional Investors Weigh In On SiBone

Large investors have recently added to or reduced their stakes in the stock. Johnson Investment Counsel Inc. bought a new stake in SiBone during the first quarter worth approximately $148,000. Rhumbline Advisers increased its stake in SiBone by 3.6% during the first quarter. Rhumbline Advisers now owns 59,721 shares of the company’s stock worth $838,000 after acquiring an additional 2,100 shares during the last quarter. GAMMA Investing LLC increased its stake in SiBone by 20,352.6% during the first quarter. GAMMA Investing LLC now owns 3,886 shares of the company’s stock worth $55,000 after acquiring an additional 3,867 shares during the last quarter. MetLife Investment Management LLC increased its stake in SiBone by 17.6% during the fourth quarter. MetLife Investment Management LLC now owns 27,421 shares of the company’s stock worth $384,000 after acquiring an additional 4,104 shares during the last quarter. Finally, Deutsche Bank AG grew its stake in shares of SiBone by 53.0% during the fourth quarter. Deutsche Bank AG now owns 36,268 shares of the company’s stock valued at $508,000 after buying an additional 12,561 shares during the last quarter. 98.11% of the stock is owned by institutional investors.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.